Clinical Trial Update: Lucentis to Treat Pigment Epithelial Detachment [Phase 2]

View source ↗

Summary

Phase 2 trial of Lucentis for pigment epithelial detachment has completed, with an update on the study status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pigment Epithelial Detachment

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Pigment Epithelial Detachment | Phase 2 | Status: COMPLETED